Evaluation of antibodies to oxidized low-density lipoprotein and assessment of C-reactive protein in acute coronary syndrome and stable coronary artery disease

Thrombosis and Haemostasis

Volumn 98, Issue 2, 2007, Pages 413-419

  Soltesz, Pal ^a   Veres, Katalin ^a   Laczik, Renata ^a   Der, Henrietta ^a   Csipo, Istvan ^a   Timar, Orsolya ^a   Szomjak, Edit ^a   Szegedi, Gyula ^a   Szodoray, Peter ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Antibodies to oxidized LDL; Atherosclerosis; C reactive protein; Coronary artery disease

Indexed keywords

ACETYLSALICYLIC ACID; AUTOANTIBODY; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOCHEMICAL MARKER; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G; OXIDIZED LOW DENSITY LIPOPROTEIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART ARRHYTHMIA; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; PAIN; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT DISEASE; TURBIDIMETRY; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; AUTOANTIBODIES; AUTOIMMUNITY; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 34547872004     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-10-0561     Document Type: Article

References (35)

1. Biasucci LM, Santamaria M, Liuzzo G. Inflammation, atherosclerosis and acute coronary syndrome. Minerva Cardioangiol 2002; 50: 475-486.
2. George J, Afek A, Gilburd B, et al. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation 1998; 98: 1108-1115.
3. Goon PK, Boos CJ, Stonelake PS, et al. Detection and quantification of mature circulating endothelial cells using flow cytometry and immunomagnetic beads: a methodological comparison. Thromb Haemost 2006; 96: 45-52.
4. Sherer Y, Shoenfeld Y. Immunomodulation for treatment and prevention of atherosclerosis. Auto-immun Rev 2002; 1: 21-27. Review.
5. Veres K, Lakos G, Kerényi A, et al. Antiphospholipid antibodies in acute coronary syndrome: implications for pathogenesis and prognosis. Lupus 2004; 13: 423-427.
6. Berliner JA, Subbanagounder G, Leitinger N, et al. Evidence for a role of phospholipid oxidation products in atherogenesis, Trends Cardiov Med 2001; 11: 142-147.
7. Parthasarathy S, Wieland E, Steinberg D. A role of endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein, Proc Natl Acad Sci USA 1989; 86: 1046-1050.
8. Wu R, Nityanand S, Berglund L, et al. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arteoioscler Thromb Vasc Biol 1997; 17: 3159-3163.
9. Salonen JT, Yla Herttuala, S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883-887.
10. George J, Ahmed A, Patnaik M, et al. The prediction of coronary atherosclerosis employing artificial neural networks. Clin Cardiol 2000; 23: 453-456.
11. George J, Harats D, Bakshi E, et al. Anti-oxidized low density lipoprotein antibody determination as a predictor of restenosis following percutaneous transluminal coronary angioplasty. Immunol Lett 1999; 68: 263-266.
12. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
13. Vaarala, O. Antibodies to oxidised LDL. Lupus 2000; 9: 202-205.
14. Hasunuma Y, Matsuura E, Makita Z, et al. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol 1997; 107: 569-573.
15. Tuomisto K, Jousilahti P, Sundvall J, et al. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb, Haemost 2006; 95: 511-518.
16. DeMaria AN, Ben-Yehuda O, Berman D, et al. Highlights of the Year in JACC 2003. J Am Coll Cardiol 2003; 42: 2156-2166.
17. Ikonomidis I, Lekakis J, Kremastinos DT. Inflammatory markers for risk stratification in primary prevention of cardiovascular disease: time for a "multi-marker" approach? Thromb Haemost 2006; 95: 397-398.
18. Labarrere CA, Zaloga GP. C-reactive protein: from innocent bystander to pivotal mediator of atherosclerosis. Am J Med 2004; 117: 499-507.
19. Stemme S, Faber B, Hohn J, et al. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci 1995; 92: 3893-3897.
20. Shoenfeld Y, Wu R, Dearing L, et al. Are anti-oxidized low-density lipoprotein antibodies pathogenic or protective? Circulation 2004; 110: 2552-2558.
21. George J, Afek A, Gilburd B, et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 1998; 138: 147-152.
22. Caligiuri G, Nicoletti A, Poirier B, et al. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002; 109: 745-753.
23. Shoji T, Nishizawa Y, Fukumoto M, et al. Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects. Atherosclerosis 2000; 148: 171-177.
24. Fukumoto M, Shoji T, Emoto M, et al. Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol 2000; 20: 703-707.
25. Ylä-Herttuala S, Palinski W, Butler SW, et al. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994; 14: 32-40.
26. Bergmark C, Wu R, de Faire U, et al. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 1995; 15: 441-445.
27. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
28. Wu R, Lefvert AK. Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotope, subclass, affinity and effect on the macrophage uptake of oxLDL. Clin Exp Immunol 1995; 102: 174-180.
29. Virella G, Atchley D, Koskinen S, et al. Proatherogenic and proinflammatory properties of immune complexes prepared with purified human oxLDL antibodies and lunnan oxLDL. Clin Inummol 2002; 105: 81-92.
30. Ameli S, Hultgardh-Nilsson A, Regnstrom J, et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 1996; 16: 1074-1079.
31. Vaarala O, Puurunen M, Manttari M, et al. Antibodies to prothrombin imply a risk of myocardial infarction in middle-aged men. Thromb Haemost 1996; 75: 456-459.
32. Vaarala O. Antiphospholipid antibodies and atherosclerosis. Lupus 1996; 5: 442-447. Review.
33. Auer J, Berent R, Lassing E, et al. C-reactive protein and coronary artery disease. Jpn Heart J 2002; 43: 607-619.
34. Mirat J, Raguz M, Romic Z, et al. Inflammation markers in acute coronary syndrome. Acta Med Croatica 2004; 58: 115-117.
35. Szodoray P, Timar O, Veres K, et al. Th1/Th2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines- immunological alterations in acute coronary syndrome and stable coronary artery disease. Scand J Immunol 2006; 64: 336-344.